Drugs / MEDI-4166
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02524782 | Oct 2015 → Apr 2017 | type 2 diabetes mellitus | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI-4166 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02524782 ↗ |
| Route | Subcutaneous | “MEDI-4166 administered subcutaneously” NCT02524782 ↗ |
| Target | PCSK9 | “a PCSK9 antibody” PMID 30593607 ↗ Dec 2018 |